Drug intelligence / Profile preview

KeraStat Gel + morphine

Development stage: Preclinical
Lead developer: KeraNetics
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

KeraStat Gel + morphine is a novel topical formulation combining a keratin-based hydrogel wound dressing (KeraStat Gel) with morphine for localized pain management in chronic wounds. The formulation is designed to deliver morphine directly to wound sites, providing pain relief during dressing changes and potentially reducing the need for systemic opioid medications. KeraStat Gel acts as a protective covering that maintains a moist environment for injured skin, while the morphine component provides localized analgesia.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on KeraStat Gel + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeraStat Gel + morphine.

Explore the full profile